Advanced Search

 

Study ID Status Title Patient Level Data
49653/439 Completed A 2 years pharmacovigilance study to assess the safety of oral prescription medicine AVANDIA 4mg and 8 mg daily in conjunction with sulfonylurea or metformin , in patients with type-2 diabetes mellitus.
49653/452 Completed A randomized, double-blind, parallel group, placebo-controlled study to investigate the safety, tolerability and efficacy of six months' administration of AVANDIA (rosiglitazone maleate) in subjects with Relapsing-Remitting Multiple Sclerosis (MS) Study Listed on ClinicalStudyDataRequest.com
49653/454 Completed A Single-blind, Randomised, Positive-controlled, Parallel-group Multicentre Study to Compare the Effect of Glibenclamide plus Rosiglitazone vs Glibenclamide plus Placebo on Body Fat Distribution When Administered for 12 Months to Korean Patients with Type 2 Diabetes Mellitus.
49653/902 Completed An Open-label Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Rosiglitazone when Co-administered with Gemfibrozil in Healthy Adult Subjects Study Listed on ClinicalStudyDataRequest.com
49653/903 Completed A randomized, open-label, two-period crossover study to demonstrate the bioequivalence of twice-daily immediate release and once-daily extended release rosiglitazone dosing over five days in healthy volunteers. Study Listed on ClinicalStudyDataRequest.com
497115/003 Completed A Double-Blind, Randomized, Multicenter, Placebo-Controlled, Parallel Group, Dose Ranging Study to Assess the Efficacy, Safety, and Pharmacokinetics of an Oral Thrombopoietin Receptor Agonist(SB497115-GR) Administered at 50, 75, and 100 mg to Cancer Patients Receiving Multiple Cycles of Chemotherapy
51 Completed Repeated bioequivalence study of US 100 mg Lamictal® compressed tablets, US 100 mg Lamictal® dispersible/chewable tablets and UK 100 mg Lamictal® dispersible/chewable tablets in healthy adult male volunteers.
54 Completed Disposition of Bupropion in Healthy volunteers and subjects with alcoholic liver disease. Extensive searching has revealed that no clinical study report is available for this study. The clinical trial results were reported via publication; see citation below.
548-01 Completed GG548 (naratriptan) Phase I study (single oral dose study in healthy male volunteers).
552002 Completed A Phase III, Multicenter, Randomized, Double-blind, Parallel Group Study to Evaluate the Safety and Efficacy of a New Chemical Entity for the Prevention of Postoperative Nausea and Vomiting in Female Subjects at High Risk for Emesis
58 Completed A Double-Blind, Placebo-Controlled Trial of Bupropion SR for SSRI-Induced Sexual Dysfunction – Extensive searching has revealed that no clinical study report is available for this study. The clinical trial results were reported via publication; see citation below.
580299/001 Completed A double-blind, placebo-controlled, randomised study of the efficacy of an HPV-16/18 VLP vaccine in the prevention of HPV-16 and/or HPV-18 cervical infection in healthy adolescent and young adult women in North America and Brazil. Study Listed on ClinicalStudyDataRequest.com
580299/002 Completed A Phase I Study of the Safety and Immunogenicity of MEDI-517, a Vaccine Against Human Papillomavirus Types 16 and 18, in Healthy Adult Female Volunteers. Study Listed on ClinicalStudyDataRequest.com
580299/003 Completed A Phase I/II Study to evaluate the safety and immunogenicity of MEDI-517, a virus-like particle vaccine against human papillomavirus (HPV) types 16 and 18, in healthy adult female volunteers who are HPV-16 or HPV-18 DNA positive Study Listed on ClinicalStudyDataRequest.com
580299/004 Completed Study to Evaluate the Safety and Immunogenicity of MEDI-517, a Virus-Like Particle Vaccine against Human Papillomavirus Types 16 and 18, when Formulated with Aluminum Hydroxide, AS04, or without Adjuvant, in Healthy Adult Female Volunteers Study Listed on ClinicalStudyDataRequest.com
580299/005 Completed A Phase II Double-Blind, Randomized, Dose-Comparison Study to Evaluate the Safety and Immunogenicity of MEDI-517, a Virus-Like Particle Vaccine Against Human Papillomavirus Types 16 and 18, in Healthy Adult Female Volunteers Study Listed on ClinicalStudyDataRequest.com
580299/007 Completed Study of the efficacy of candidate HPV 16/18 VLP vaccine in the prevention of HPV-16 and/or HPV-18 cervical infection in adolescent & young adult women in North America and Brazil vaccinated in primary study 580299/001 Study Listed on ClinicalStudyDataRequest.com
580299/008 Completed A phase III, double-blind, randomized, controlled, multi-center study to evaluate the efficacy of GlaxoSmithKline Biologicals. HPV-16/18 VLP AS04 vaccine compared to hepatitis A vaccine as control in prevention of persistent HPV-16 or HPV-18 cervical infection and cervical neoplasia, administered intramuscularly according to a 0, 1, 6 month schedule in healthy females 15-25 years of age. Study Listed on ClinicalStudyDataRequest.com
580299/009 Completed Study of the efficacy of an HPV16/18 VLP vaccine in the prevention of advanced cervical intraepithelial neoplasia (CIN2, CIN3, adenocarcinoma in situ and invasive cervical cancer) associated with HPV16 or HPV18 cervical infection in healthy young adult women in Costa Rica.
580299/011 Completed An observer-blind, randomized, controlled study to assess the immunogenicity and safety of GlaxoSmithKline Biologicals' HPV vaccine administered intramuscularly according to a 0, 1, 6 month schedule in healthy male subjects aged 10-18 years Study Listed on ClinicalStudyDataRequest.com
580299/012 Completed Immunogenicity: 3 consecutive lots of GSK Biologicals’ HPV-16/18 vaccine administered intramuscularly at 0,1,6 month schedule in healthy females aged 10–25 years and demonstrate non-inferiority of candidate HPV vaccine manufactured by modified production process Study Listed on ClinicalStudyDataRequest.com
580299/013 Completed Evaluate the safety and immunogenicity of GSK Biologicals’ HPV-16/18 vaccine administered intramuscularly according to a 0,1,6 month schedule in healthy female subjects (10 – 14 years) Study Listed on ClinicalStudyDataRequest.com
63102 Completed A single, rising dose study of the safety, tolerability, pharmacokinetics and pharmacodynamics of subcutaneous Org31540/SR90107A in healthy male and female elderly volunteers
63103 Completed A repeated rising-dose, placebo-controlled study of the safety, tolerability, pharmacokinetics and pharmacodynamics of subcutaneous Org31540/SR90107A administered for 7 consecutive days to healthy male and female elderly volunteers
63105 Completed A study to evaluate safety, tolerability and pharmacokinetics of 2, 4, 6, 12, 16,18, and 20 mg of the pentasaccharide Org31540/SR90107A, administered as a single intravenous bolus injection to healthy elderly subjects

 

 

For more information on this register please email GSKClinicalSupportHD@gsk.com

GSK-sponsored clinical studies are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party.
GSK-sponsored clinical trials are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party.

ClinicalTrial.gov is a database that provides summary protocol information for ongoing clinical trials.

IFPMA.org is a search portal provided by the International Federation of Pharamceutical Manufacturers & Associations (IFPMA).

This portal provides a single entry point to search for industry sponsored clinical trials which are on existing registers and databases.

EU Clinical Trials Register is a database of all clinical trials commencing in the European Community from 1 May 2004 onwards. It has been established in accordance with Directive 2001/20/EC.